



DT18 PCT/PTO 22 OCT 2002 PCT #12

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/623,548	
	Filing Date	September 5, 2000	
	First Named Inventor	BRIDON et al.	
	Group Art Unit	1646	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	464	Attorney Docket No.	500862002100

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Authorized to Charge Deposit Account	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s): <b>Postcard.</b>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Response to Notification of Missing Requirements Under 35 USC 371 - 2 pgs
<input type="checkbox"/> Second Supplemental Information Disclosure Statement - 3 pgs	<input type="checkbox"/> Request for Refund	1. Copy of NOTICE - 2 pgs
<input type="checkbox"/> Form PTO-1449 - 1 pg (with Reference attached)	<input type="checkbox"/> CD, Number of CD(s) _____	2. Sequence List (printed paper copy) - 459 pgs
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	3. Sequence List (computer readable form) - 1 disk
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input checked="" type="checkbox"/> Response to Notification of Missing Requirements Under 35 U.S.C. 371 in the US Designated/Elected Office (DO/EO/US)		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Morrison & Foerster LLP 425 Market Street San Francisco, California 94105-2482 Michael R. Ward, Reg. No. 38,651
Signature	<i>Michael R Ward</i>
Date	October 18, 2002

<b>CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"</b>
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on October 18, 2002.
<i>[Signature]</i> LILIA OLSEN



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/623,548	Dominique P. Bridon	REDC-2110-US

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US00/13576

I.A. FILING DATE	PRIORITY DATE
05/17/2000	05/17/1999

20872  
 MORRISON & FOERSTER LLP  
 425 MARKET STREET  
 SAN FRANCISCO, CA 94105-2482

CONFIRMATION NO. 4825

371 FORMALITIES LETTER



\*OC00000008799336\*

Date Mailed: 09/17/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of the International Application
- Copy of the International Search Report
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Request for Immediate Examination
- Small Entity Statement
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- APPLICANT MUST PROVIDE:
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHAKEEL AHMED

Telephone: (703) 305-3659

**PART 2 - OFFICE COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/623,548	PCT/US00/13576	REDC-2110-US

PATENT  
Docket No. 500862002100  
Clt Ref: REDC-2110

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on **October 18, 2002**.

  
LILIA OLSEN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Dominique P. BRIDON et al.

Serial No.: 09/623,548

Filing Date: September 5, 2000

For: PROTECTION OF ENDOGENOUS  
THERAPEUTIC PEPTIDES FROM  
PEPTIDASE ACTIVITY THROUGH  
CONJUGATION TO BLOOD  
COMPONENTS

Examiner: To Be Assigned

Group Art Unit: 1646

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C.  
371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)  
MAILED SEPTEMBER 17, 2002**

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the *Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)*, mailed September 17, 2002. Please find enclosed a paper and computer-readable copy of the Sequence Listing. To the best of the undersigned's knowledge, the printed Sequence Listing is identical to the Sequence Listing submitted in computer-readable form.

A copy of the *Notification of Missing Requirements* is attached hereto as required by United States Patent Office rules governing gene sequences.

Applicant notes that amino acid identified as "Xaa" in SEQ ID NO: 356 did not have a mandatory feature defining the variant in the Sequence Listing as originally filed. This mandatory feature has been included in the attached Sequence Listing.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required as a result of this statement, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due to our **Deposit account no. 03-1952** referenced Docket No.

**500862002100**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 18, 2002

By: Michael R. Ward  
Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522